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This randomized, double-blind, double-dummy, multicentre cross-over study compared the eects on the
hypothalamic-pituitary-adrenal (HPA) axis of fluticasone propionate (750 mg twice daily given via the DiskusTM
and budesonide (800 mg twice daily given via the TurbuhalerTM. Two treatment periods of 2 weeks each were
preceded by a 2-week run-in period and separated by a 2-week washout period. During run-in and washout,
patients received beclomethasone dipropionate (BDP) or budesonide at a constant dose of 1500–1600 mg day71.
Sixty patients aged 18–75 years with moderate to severe asthma not fully controlled by treatment with 1500–1600
mg day71 budesonide or BDP entered run-in and 45 completed the study. HPA axis suppression was assessed by
morning serum cortisol (area under the curve from 0800 to 1030 hours) and 12-h nocturnal urinary cortisol
excretion, measured at the end of run-in (baseline 1), at the end of washout (baseline 2), and at the end of each
treatment period.
Neither budesonide nor fluticasone produced significant suppression of either parameter compared to baselines.
Only a few patients had serum-cortisol and urinary cortisol values below the normal range, before and after
treatment. This shows that the patients did not have adrenal suppression before entering the study. The ratio
between the AUC serum cortisol measured after fluticasone treatment and after budesonide treatment was 099
(95% CI 092–106), indicating equivalent eects on the HPA axis. This result was achieved after having omitted
two patients’ results, due to their very sensitive reaction to budesonide, but not to fluticasone. Two exacerbations of
acute asthma occurred during budesonide treatment and none during fluticasone treatment. Both treatments were
well tolerated. In conclusion, budesonide 1600 mg day71 via TurbuhalerTM and fluticasone propionate 1500 mg
day71 via DiskusTM had no clinical eects on the HPA axis in patients with moderate to severe asthma.
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Inhaled corticosteroids are now well established in the
treatment of asthma, and are considered to have an
essential role in the management of most asthmatic patientsReceived 29 October 1998 and accepted in revised form 26
November 1999.
Correspondence should be addressed to: Dr Nils Ringdal, Molde
Internal Medicine Centre, Strandgt. 3, N-6400 Molde, Norway.
0954-6111/00/050482+08 $35?00/0(1). Guidelines on asthma management published in
Europe and the U.S.A. recommend the use of inhaled
corticosteroids as first-line therapy in all but the mildest
cases of asthma (2,3).
Although inhaled corticosteroids have a far lower
potential for systemic eects than oral corticosteroid
therapy, this potential is not zero and the systemic eects
of long-term inhaled corticosteroid therapy have been much
studied in recent years (for a review, see reference 1). Long-
term therapy at high doses may sometimes produce# 2000 HARCOURT PUBLISHERS LTD
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easy bruising (4,5). Other potential systemic eects include
suppression of the hypothalamic-pituitary-adrenal (HPA)
axis, reduced bone density and growth impairment in
children (6). Of these, HPA suppression is the most
sensitive and easily measured marker of the systemic
activity of inhaled corticosteroids (1).
Systemic exposure to inhaled corticosteroids occurs via
two routes. Part of an inhaled dose is deposited in the lower
airways and absorbed into the pulmonary circulation. The
remainder, which may be up to 80% (7), is deposited in the
mouth and on the back of the throat. Unless rinsed out, it
will eventually be swallowed and absorbed through the gut.
Some may be inactivated by first-pass metabolism in the
liver, and the rest will reach the systemic circulation.
At the doses required by most adult asthmatics, up to
approximately 800 mg day71 of beclomethasone dipropio-
nate (BDP) or budesonide (BUB), inhaled corticosteroids
have an excellent safety profile (8). However, in adults with
moderate to severe asthma, doses of up to 2000 mg day71 of
BDP may be required to achieve satisfactory disease control
(3). Significant HPA axis suppression has been observed in
adults receiving BDP at doses in excess of 1000 mg day71
(9) or 1500 mg day71 (6). Therefore, there is a need for an
inhaled corticosteroid with high potency but low potential
for systemic eects, even at high doses.
Fluticasone propionate (FP) has the highest receptor
anity of the inhaled corticosteroids in clinical use (10–12)
and has been shown to be more potent than either BDP or
BUD in a variety of in vitro models (13–17). These results
are supported by clinical studies, which consistently report
that FP is at least as ecacious as twice the microgram dose
of either BDP (18, 19) or BUD (20–23), across a dose range
of FP from 200 to 800 mg day71. At doses of up to 2000 mg
day71 in patients with severe asthma, FP is more eective
than an equal dose of BDP (24) or BUD (25). Moreover
FP has negligible oral bioavailability, as it is subjected to
near-complete first-pass metabolism in the liver (26,27).
This eectively eliminates the oral route for systemic
absorption.
In patients with severe asthma, 1500 mg day71 FP
produces no more HPA suppression than an equal dose of
BDP (24). A higher FP dose (2000 mg day71) produces a
greater suppression of serum cortisol than 1600 mg day71
BUD, but values still remain within the normal range (25).
However, a study in healthy adult volunteers has reported
that FD produces greater suppression of the HPA axis than
BUD over the dose range of 400–2000 mg day71
administered by metered-dose inhaler (28).
In the above-mentioned studies, the inhalation devices used
were metered dose inhalers (MDIs) or Diskhaler. Nowa-
days, the dry-powder devices DiskusTM (Glaxo Wellcome,
London, U.K.) and TurbuhalerTM (Astrazeneca, Lund,
Sweden) are most frequently used, at least in Scandinavia
(36). The present study was carried out to compare the
HPA-suppressing eects of FP (1500 mg day71) and BUD
(1600 mg day71) given via dry-powder inhalation devices
(DiskusTM and TurbuhalerTM, respectively) as a primary
objective in adult patients with moderate to severe asthma
who require these specific high doses of steroid treatment.Methods
STUDY DESIGN
The study was a randomized, double-blind, double-dummy,
cross-over study (Fig. 1). Two treatment periods of 2 weeks
each were separated by a 2-week washout period and
preceded by a 2-week run-in. Study visits took place prior
to run-in, after the run-in period (baseline 1), after the first
treatment period, after the washout period (baseline 2) and
after the second treatment period.
During the run-in and washout periods, patients received
their usual medication for reversible obstructive airways
disease, which could include inhaled corticosteroids (BDP
or BUD), oral xanthine derivatives, sodium cromoglycate,
long-acting b2-agonists, anti-histamines, inhaled anti-cho-
linergics and oral b2-agonists. All medication doses were
held constant throughout the study. The same inhaled
corticosteroid was used during the run-in and washout
periods. Compliance was checked by counting doses left
over on the DiskusTM.
During the two treatment periods, the patients’ usual
inhaled corticosteroid was replaced by study medication.
This was either FD 750 mg twice daily via the DiskusTM dry
powder inhaler or BUD 800 mg twice daily via the
TurbuhalerTM, each with a matching placebo to maintain
study blinding. Patients were randomized to receive either
FD or BUD for the first treatment period, and then
switched to the other for the second treatment period.
Short-acting b2-agonists, salbutamol or terbutaline, were
permitted as rescue medication throughout the study.
The study was conducted in accordance with the
Declaration of Helsinki (Hong Kong Amendment 1989),
and was approved by the regional Ethical Committee in
each country. All patients gave written informed consent
for study participation.
PATIENTS
Patients were aged 18 to 75 years, with a clinical history of
reversible obstructive airways disease responding to inhaled
corticosteroids. All patients had been receiving inhaled
corticosteroids for at least the last 3 months, and BUD
(1600 mg day71) or BDP (1500–1600 mg day71) at a
constant dose for 4 weeks prior to randomization at Visit 1.
They were required to demonstrate correct use of the
DiskusTM and TurbuhalerTM devices and a peak flow
meter. Forced expiratory volume in 1 sec (FEV1) was
measured at Visits 1 and 2 and was required to be 50% or
more of the predicted value on each occasion. All patients
had to show a clear response to bronchodilator therapy.
This was defined by comparing the peak expiratory flow
(PEF) value obtained before inhaling any bronchodilator
with the PEF obtained after inhalation of salbutamol. The
mean morning PEF obtained before taking any medication
on each of the last 7 days of the run-in period could be no
more than 90% of the PEF obtained after inhalation of
400–800 mg salbutamol at Visit 2. Patients must also have
experienced asthma symptoms (total diary card score of at
FIG. 1. Study design. PRN salbutamol/terbutaline on-demand salbutamol or terbutaline as required.
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on at least two occasions per 24 h, on at least 4 days during
the run-in period. These selection criteria defined a patient
group with moderate to severe symptomatic reversible
obstructive airways disease.
Patients were excluded from the study for the following
reasons: very poorly controlled asthma or chronic obstruc-
tive pulmonary disease; use of oral, parenteral or depot
corticosteroids in the 4 weeks preceding Visit 1; pregnancy
(or likelihood of becoming pregnant) or lactation in
women; evidence of alcohol or drug abuse; known or
suspected hypersensitivity to inhaled steroids; respiratory
tract infection or hospitalization for respiratory disease in
the 4 weeks prior to Visit 1; night shift work; evidence of
serious uncontrolled systemic, psychological or other
disease likely to interfere with the conduct of the study.
ASSESSMENTS
The primary ecacy variables were morning serum cortisol
measured over the period from 0800 to 1030 hours for
calculation of area under the curve (AUC), and 12-h
nocturnal urinary cortisol excretion. Both these assessmentsare recognized measures of HPA axis function, and 12-h
nocturnal urine cortisol excretion is regarded as the more
sensitive of the two (1). Serum samples were taken at 0800,
0830, 0900, 0930, 1000 and 1030 hours at Visits 2, 3, 4
and 5, and urine was collected from 2000 to 0800 hours on
the nights prior to Visits 2, 3, 4 and 5. Cortisol
concentrations in serum and urine samples were determined
by a central laboratory (CALAB, Sweden).
FEV1 was measured at each visit using a spirometer and
the highest of three measurements recorded. PEF was
measured by the patients each morning (between 0700 and
0900 hours) and evening (between 1900 and 2100 hours)
using a peak flow meter, and the highest of three
measurements recorded on a diary card. Daytime asthma
symptoms were assessed by the patients and recorded on a
diary card, using a six-point scale (0no symptoms,
1symptoms for one short period, 2symptoms for two
short periods, 3symptoms for most of the day but not
interfering with normal activities, 4symptoms for most of
the day which interfered with normal activities,
5symptoms for most of the day which prevented
performance of normal activities). Nocturnal asthma
symptoms were assessed and recorded in a similar manner,
using a slightly dierent scale (0no symptoms,
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early, 2symptoms causing the patient to wake twice or
more, 3symptoms keeping the patient awake most of the
night, 4symptoms preventing the patient from sleeping at
all). These measurements were used only in the run-in
period to determine patients’ eligibility for the trial and
were not formally analysed.
STATISTICAL ANALYSIS
Forty patients would enable a treatment ratio of less than
080 and greater than 125 to be detected with 90% power
at the 5% significance level. Approximately 60 patients
were to be recruited, with the aim of obtaining 40 evaluable
patients at the end of the study.
Previously performed cross-over studies showed that a
washout period of 2 weeks should be sucient for cortisol
suppresion to recover (28, 37, 38). In these studies, the
washout period lasted from 3 to 14 days. Our 2-week
washout period was therefore considered adequate to
eliminate any carry-over eect from the first to the second
treatment period, and therefore formal assessment of carry-
over eect was not performed.
Categorical variables were described using frequency
distributions, and continuous variables were described
using the mean and standard deviation (SD).
AUC serum cortisol for the period 0800–1030 hours
was calculated using the trapezoidal rule. Analysis of
covariance (ANCOVA) for cross-over trials (29) at the end
of each treatment period (Visits 3 and 5) was performed
using the appropriate baseline value (Visits 2 and 4,
respectively) as the covariate. Variations in period, study
centre and treatment were allowed for in the analysis. To
remove between-patient variability, a nested eect of
patient and sequence was included in the model. Twelve-
hour urine cortisol excretion was similarly compared. A
treatment ratio with corresponding one-sample 95%
confidence interval (95% CI) was calculated as the ratio
between AUC serum cortisol after FD and after BUD. AllTABLE 1. Patient characteristics
Demographic variable Pat
to
Mean (SD) age, years
Sex, n (%)
Women
Men
Mean (SD) FEV1% of pred
Duration of reversible obstructive airways
disease 415 years, n (%)
Current smokers, n (%)
Previous inhaled corticosteroid, n (%)
BUD 1600 mg day71
BDP 1600 mg day71
BDP 1500 mg day71tests for significance were two-tailed, and a P-value of
5005 was considered significant. Statistical analysis was
conducted using SAS software (SAS Institute, Cany, NC,
U.S.A.).
Results
Sixty patients entered the run-in period, of whom 48 met all
the eligibility criteria and were randomized to treatment.
Forty-five patients completed the study. Demographic
information is given in Table 1. The three patients who
discontinued treatment all withdrew from the trial because
of adverse events while they were receiving BUD (one for
pneumonia, one for asthma deterioration, and one because
of the medicinal taste of the study treatment).
Before treatment, the mean serum cortisol concentration
at 0800 hours was 389.5 nmol 171 in the BUD group. The
corresponding values after treatment were 3911 nmol 171
and 3974 nmol 171 respectively. The numbers of patients
having serum cortisol values below the normal range were
four before treatment with FP and one after treatment with
FP. The corresponding numbers before and after treatment
with BUD were two and three, respectively. The corre-
sponding numbers for urinary cortisol were 10 and seven
for FP, and 11 and 10 for BUD. The eect on mean serum
cortisol from 0800 to 1030 hours was similar for both
treatment periods (Fig. 2).
Table 2 shows mean serum cortisol AUC values by
treatment sequence and treatment period. Serum cortisol
was not influenced by treatment sequence (P023), and
there were no statistically significant dierences between FP
and BUD (P063) after controlling for baseline values and
study centre.
The ratio between the serum cortisol value observed after
FP and that observed after BUD was 120 (95% CI 092–
147). Two patients, however, exhibited a very sensitive
reaction to BUD but not to FP (serum cortisol AUC of
6345 and 7390 nmol l71 after FP, compared with 1655ients randomized
treatment (n48)
Patients entering run-in
only (n12)
500(146) 522(135)
14 (29) 6 (50)
34 (71) 6 (50)
767(159) 743(219)
29(604) 6 (500)
11 (229) 1 (83)
38 (792) 10 (833)
8 (167) 2 (167)
2 (41) 0
FIG. 2. Mean (SD) serum cortisol over the period 0800–
1030 hours for each study treatment period. SD shown in
one direction only for clarity. (  ), FP 1500 mg; (—),
BUD 1600 mg.
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these two patients from the analysis gave a treatment ratio
of 099 (95% CI 092–106), clearly indicating that the two
drugs had equivalent eects on the HPA axis.
Fig. 3 presents serum cortisol AUC at baselines and each
treatment period for individual patients. In agreement with
the mean data shown in Table 2, there was no general
pattern of suppression by either treatment. The two
patients who exhibited high sensitivity to BUD but not
FP may be readily identified.
Twelve-hour nocturnal urine cortisol excretion also
showed that both treatments had clinically equivalent
eects on the HPA axis. Table 3 presents mean nocturnal
urinary cortisol excretion by treatment sequence and
treatment group. There was no statistically significant
dierence between FP and BUD (P080) after controlling
for baseline values and study centre, and urine cortisol was
not influenced by treatment sequence (P030).
Individual patient data for urine cortisol by treatment
period confirm the above finding.
Both FP and BUD were well tolerated. A total of 20
patients reported 29 adverse events, of which the majority
occurred in the run-in and washout phases (Table 4).TABLE 2. AUC values for serum cortisol by treatment period an
Mean (SD) AUC serum
cortisol, nmol l71
Treatment period Fluticasone/budesonide
Run-in n24
792 (286)
Fluticasone n24
815 (295)
Washout n24
793 (290)
Budesonide n24
817 (350)Two patients experienced exacerbations of asthma while
receiving BUD treatment, compared to none during FP
treatment. The other three adverse events which occurred
during BUD treatment were abdominal pains, medicinal
taste and pneumonia. Medicinal taste was considered
‘almost certainly’ to be related to the study treatment but
the other events were considered to be unrelated to the
study treatment. Both the adverse events which occurred on
FP treatment (one patient had mild tonsilitis, and one cut
o part of a toe) were considered unrelated to the study
medication.
In run-in, the following adverse events were reported:
three common cold, one each of erysipelas, gastroenteritis,
bursitis of knee, hardening inside lower lip, lumbago,
mandibular osteitis and influenza.
In the wash-out period, the adverse events reported were:
three common cold, and one each of pruritis of vulva,
increased coughing, trauma on left foot, fever, cough, low
back pain, thoracic pain, headache, rupture of muscle.
Discussion
This study found that FP 1500 mg day71 via the DiskusTM
dry powder device and BUD 1600 mg day71 via the
TurbuhalerTM were equivalent in their eects on the HPA
axis in patients with moderate to severe asthma. Neither
treatment produced significant suppression of morning
serum cortisol or 12-h nocturnal urine cortisol.
These findings are in agreement with previous studies in
patients with moderate to severe asthma. A 12-month study
comparing 1500 mg day71 FP and an equal dose of BDP
found that there were no dierences in morning plasma
cortisol, urinary free cortisol or response to adrenocorti-
coptrophic hormone, and neither treatment showed any
evidence of plasma cortisol suppression (24). A shorter, 6-
week study in patients with chronic severe asthma
compared FP (1000 mg day71 or 2000 mg day71) with
BUD (1600 mg day)71 (25). Neither FP 1000 mg day71 nor
1600 mg day71 suppressed mean plasma cortisol below
baseline levels, and although FP 2000 mg day71 didd treatment sequence
Treatment sequence
Budesonide/fluticasone Overall
n22 n46
773 (288) 783 (284)
n21 n45
746 (234) 783 (268)
n21 n45
777 (237) 786 (264)
n21 n45
762 (244) 791 (303)
TABLE 3. Twelve-hour nocturnal urine cortisol by treatment period and treatment sequence
Mean (SD) 12 h
nocturnal urine
cortisol, nmol 12 h71
Treatment sequence
Treatment period Fluticasone/budesonide Budesonide/fluticasone Overall
Run-in n23 n23 n46
768 (305) 859 (580) 814 (461)
Fluticasone n24 n21 n45
754 (432) 677 (341) 718 (390)
Washout n24 n21 n45
753 (392) 605 (335) 684 (370)
Budesonide n23 n20 n43
620 (312) 697 (445) 656 (376)
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baseline, the mean level remained well within the normal
range. A meta-analysis of 14 clinical studies, comparing FP
(200–1000 mg day71) with twice the microgram dose of
BUD or BDP, found that cortisol suppression with FP was
less than that observed with BUD and no greater than that
observed with BDP (30).
A study in healthy volunteers has claimed that FP has a
greater eect on the HPA axis than budesonide. A 4-day
repeat-dose study compared BUD (200 mg, 400 mg and 1000
mg twice daily) with FP (200 mg, 375 mg and 1000 mg twice
daily) and reported that 24-h pooled plasma cortisol levels
were significantly lower during FP than BUD treatment at
all dose levels (28). This was also shown in a cross-over
study with 12 mild asthmatics using high doses of FP and
BUD inhaled via a MDI (35). These results are at variance
with the results of much larger and longer-term clinical
studies in asthmatic patients (24, 25), and the relevance of
studies in healthy volunteers to patients with moderate to
severe asthma has been questioned (1).
There is some evidence that patients with asthma and
healthy volunteers may dier in their handling of FP.
Repeat-dose pharmacokinetic studies of 500 mg FP given
twice daily found that plasma FP concentrations at steady
state in healthy volunteers were twice as high as those inTABLE 4. Adverse events (AES) by treatment period
Treatment period Patients experiencing
AES (n)
AES (n)
Run-in 8 10
Fluticasone 2 2
Washout 5 12
Budesonide 5 5
Total 20 29patients with asthma (31, 32). It appears that healthy
volunteers absorb more of an inhaled corticosteroid dose
from the lung than asthmatic patients, possibly because of
dierences in airway patency (33). This raises further
doubts over the validity of healthy volunteer studies as a
method of assessing the probable systemic side-eects of
inhaled corticosteroids.
This study could be criticized in that the patients were
already being treated with high doses of inhaled steroids,
and that this could already have had an eect on the HPA-
axis. However, very few patients had values below normal
levels, and their disease was not progressing while they were
under treatment. Our aim was to investigate the eect on
the HPA-axis as a primary endpoint in patients who require
these high doses. It would have been inappropriate to select
patients on low doses or even steroid-naive patients for the
study in order to treat them with high doses which they
clinically did not require. The rationale for performing a
short-term cross-over study was to let the patients be their
own controls.
It may also be put forward that this study does not
provide any new information in addition to that from
previously performed studies. As the devices used in
previous mentioned studies are mostly MDIs, we felt that
it was important to investigate the eect on the HPA-axis
using dry powder devices such as the DiskusTM and
TurbuhalerTM, as these are the most commonly used
inhalation devices in clinical practice in Scandinavia today.
A meta-analysis of 14 clinical studies has reported that
FP is at least as eective as twice the microgram dose of
BUD and BDP, over the dose range of 200–1000 mg day71
FP (30), and more eective in equal doses (24,25). Recently,
it has been reported that FP 1500 mg day71 has a greater
oral steroid-sparing eect than BUD 1600 mg day71 in
chronic severe asthma (34). Taking this evidence of greater
ecacy at equal doses in conjunction with the present
study’s confirmation of equivalent systemic activity at
almost equal doses in asthmatic patients, it appears that
FP may have a better therapeutic ratio than BUD. FP
oers the potential for improved disease control in patients
488 N. RINGDAL ET AL.with moderate to severe asthma, with no increase in
systemic side-eects.
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